VNDA Projected Dividend Yield
Vanda Pharmaceuticals Inc ( NASDAQ : VNDA )Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications. 20 YEAR PERFORMANCE RESULTS |
VNDA Dividend History Detail VNDA Dividend News VNDA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |